Form 4: Sandell Scott D Reports Beneficial Ownership Changes in MBX Biosciences, Inc.

Scott D. Sandell, a director and indirect owner of more than 10% of MBX Biosciences, Inc., reports changes in beneficial ownership following the company's initial public offering.

Summary

• Scott D. Sandell, a director of MBX Biosciences, Inc., filed a Form 4 detailing changes in his beneficial ownership of the company's stock.
• On September 16, 2024, Series A and Series B Convertible Preferred Stock were converted into common stock immediately prior to the closing of MBX Biosciences' initial public offering.
• The conversion resulted in Sandell indirectly acquiring 1,023,103 shares of common stock from Series A Preferred Stock and 2,091,383 shares from Series B Preferred Stock.
• Sandell also purchased 500,000 shares of common stock at $16 per share on the same day.
• Following these transactions, Sandell indirectly beneficially owns 3,614,486 shares of common stock.
• Sandell disclaims beneficial ownership of the securities held by NEA 17 in which he has no pecuniary interest.

Sentiment

Score: 6

Explanation: The document is a standard regulatory filing related to an IPO, so the sentiment is neutral. It reflects necessary transactions and disclosures.

Industry Context

Form 4 filings are standard practice for insiders of publicly traded companies to report changes in their ownership positions, providing transparency to investors.

Stakeholder Impact

• Shareholders are informed of changes in beneficial ownership by a director.
• The filing provides transparency regarding insider transactions related to the IPO.

Key Dates